Related Experiment Video
Updated: Sep 15, 2025
08:46
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.5K
Chimeric antigen receptor T-cell therapy for multiple myeloma
1Judy and Bernard Briskin Center for Multiple Myeloma Research, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
Current Opinion in Oncology
|July 17, 2025
Summary
Chimeric antigen receptor T-cell (CAR T) therapy shows promise for relapsed, refractory multiple myeloma (RRMM). Approved CAR T agents are effective, but delayed neurotoxicities require careful consideration for treatment decisions.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Relapsed, refractory multiple myeloma (RRMM) is a challenging hematologic malignancy.
- Chimeric antigen receptor T-cell (CAR T) therapy has emerged as a significant advancement.
Purpose of the Study:
- To review the current standard of care for RRMM using CAR T-cell therapy.
- To discuss investigational CAR T products and their potential impact.
Main Methods:
- Literature review of FDA-approved CAR T agents.
- Analysis of clinical trial data for novel CAR T constructs.
- Evaluation of efficacy and safety profiles, including neurotoxicity.
Main Results:
- Two CAR T agents, idecabtagene vicleucel and ciltacabtagene autoleucel, are approved and demonstrate high efficacy, moving to earlier lines of therapy.
- Delayed neurotoxicities are a key consideration.
- Ciltacabtagene autoleucel is being investigated in frontline settings and smoldering myeloma.
Conclusions:
- CAR T therapy represents a rapidly evolving and promising treatment modality for RRMM.
- Ongoing research into novel CAR T constructs and treatment sequencing aims to further improve patient outcomes.
